Abstract
Introduction: Tuberous sclerosis complex (TSC) is a genetic disease affecting 1:6000 newborns. It is a multisystem disease caused by overactivation of mechanistic target of rapamycin (mTOR) pathway and associated with the development of many benign tumors in different organs (e.g. brain, skin, kidney, lungs, heart) and comorbidities including epilepsy, cognitive impairment, neuropsychiatric disorders. In recent years, some new therapeutic agents and strategies have emerged for TSC. Areas covered: In the article, authors discuss the results of recent studies particularly on epilepsy management including preventive antiepileptic treatment in TSC infants, current studies on cannabidiol, and an increasing role of mTOR inhibitors (sirolimus, everolimus) in the treatment of many TSC manifestations. Expert opinion: Recent years and studies resulted in significant progress in the therapy of TSC. Prevention of epilepsy in TSC children with subsequent improvement of cognitive outcome is currently possible. The question about the duration of preventive treatment in children who did not experience seizures will still be open. Considering the increasing role of mTOR inhibitors, the possibility of not only therapeutic but also preventive role of these drugs for TSC manifestations may be a question for future research.

This publication has 75 references indexed in Scilit: